CD4+ Th cells play a key role in orchestrating immune responses, but the identity of the CD4+ Th cells involved in the antitumor immune response remains to be defined. We analyzed the immune cell infiltrates of head and neck squamous cell carcinoma and colorectal cancers and identified a subset of CD4+ Th cells distinct from FOXP3+ Tregs that coexpressed programmed cell death 1 (PD-1) and ICOS. These tumor-infiltrating lymphocyte CD4+ Th cells (CD4+ Th TILs) had a tissue-resident memory phenotype, were present in MHC class II–rich areas, and proliferated in the tumor, suggesting local antigen recognition. The T cell receptor repertoire of the PD-1+ICOS+ CD4+ Th TILs was oligoclonal, with T cell clones expanded in the tumor, but present at low frequencies in the periphery. Finally, these PD-1+ICOS+ CD4+ Th TILs were shown to recognize both tumor-associated antigens and tumor-specific neoantigens. Our findings provide an approach for isolating tumor-reactive CD4+ Th TILs directly ex vivo that will help define their role in the antitumor immune response and potentially improve future adoptive T cell therapy approaches.
Rebekka Duhen, Olivier Fesneau, Kimberly A. Samson, Alexandra K. Frye, Michael Beymer, Venkatesh Rajamanickam, David Ross, Eric Tran, Brady Bernard, Andrew D. Weinberg, Thomas Duhen
Title and authors | Publication | Year |
---|---|---|
Single cell profiling of circulating autoreactive CD4 T cells from patients with autoimmune liver diseases suggests tissue imprinting
Cardon A, Guinebretière T, Dong C, Gil L, Ado S, Gavlovsky PJ, Braud M, Danger R, Schultheiß C, Doméné A, Paul-Gilloteaux P, Chevalier C, Bernier L, Judor JP, Fourgeux C, Imbert A, Khaldi M, Bardou-Jacquet E, Elkrief L, Lannes A, Silvain C, Schnee M, Tanne F, Vavasseur F, Brusselle L, Brouard S, Kwok WW, Mosnier JF, Lohse AW, Poschmann J, Binder M, Gournay J, Conchon S, Milpied P, Renand A |
Nature Communications | 2025 |
Identification of PIF1 as a Ferroptosis-Related Prognostic Biomarker Correlated with Immune Infiltration in Hepatocellular Carcinoma.
Liu F, Yin P, Lu L, Yao J, Jiao B |
Applied biochemistry and biotechnology | 2025 |
A Pan-Cancer Comparative Analysis of The Cancer Genome Atlas Transcriptomic TIL-Immune Signatures
Hitscherich K, Noussome D, Dinerman A, Dulemba V, Lowery F, Nilubol N |
Research Square | 2025 |
Fat-to-blood recirculation of partially dysfunctional PD-1+CD4 Tconv cells is associated with dysglycemia in human obesity.
Anna Giovenzana, Eugenia Bezzecchi, Anita Bichisecchi, Sara Cardellini, Francesca Ragogna, Federica Pedica, Federica Invernizzi, Luigi Filippo, Valentina Tomajer, Francesca Aleotti, Giulia Scotti, Carlo Socci, Giovanni Cesana, Stefano Olmi, Marco Morelli, Massimo Falconi, Andrea Giustina, Chiara Bonini, Lorenzo Piemonti, Eliana Ruggiero, Alessandra Petrelli |
iScience | 2024 |
Comparative analysis of immune infiltrates in head and neck cancers across anatomical sites
Muijlwijk T, Nijenhuis DN, Ganzevles SH, Brink A, Ke C, Fass JN, Rajamanickam V, Leemans CR, Koguchi Y, Fox BA, Poell JB, Brakenhoff RH, van de Ven R |
Journal for ImmunoTherapy of Cancer | 2024 |
The differentiation courses of the Tfh cells: a new perspective on autoimmune disease pathogenesis and treatment
Yang Q, Zhang F, Chen H, Hu Y, Yang N, Yang W, Wang J, Yang Y, Xu R, Xu C |
Bioscience Reports | 2024 |
Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances
Wang X, Yuan Z, Li Z, He X, Zhang Y, Wang X, Su J, Wu X, Li M, Du F, Chen Y, Deng S, Zhao Y, Shen J, Yi T, Xiao Z |
Frontiers in immunology | 2024 |
Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers – how to push the gas after having released the brake
Rakké YS, Buschow SI, IJzermans JN, Sprengers D |
Frontiers in immunology | 2024 |
Prognostic biomarker CPEB3 and its associations with immune infiltration in clear cell renal cell carcinoma.
Hong H, Shi X, Ou W, Ou P |
Biomedical Reports | 2024 |
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy.
Lee TA, Tsai EY, Liu SH, Hsu Hung SD, Chang SJ, Chao CH, Lai YJ, Yamaguchi H, Li CW |
Cancer research | 2024 |
Joint effects of CD8A and ICOS in Long QT Syndrome (LQTS) and Beckwith-Wiedemann Syndrome (BWS)
Meng LB, Li Y, Lv T, Lv C, Liu L, Zhang P |
Journal of Cardiothoracic Surgery | 2024 |
Radiomics Features on Enhanced Computed Tomography Predict FOXP3 Expression and Clinical Prognosis in Patients with Head and Neck Squamous Cell Carcinoma
Wang Y, Ye J, Zhou K, Chen N, Huang G, Feng G, Zhang G, Gou X |
2024 | |
PlexinB1 Inactivation Reprograms Immune Cells in the Tumor Microenvironment, Inhibiting Breast Cancer Growth and Metastatic Dissemination
Franzolin G, Brundu S, Cojocaru CF, Curatolo A, Ponzo M, Mastrantonio R, Mihara E, Kumanogoh A, Suga H, Takagi J, Tamagnone L, Giraudo E |
Cancer Immunology Research | 2024 |
The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma
Snyder M, Wang Z, Lara B, Fimbres J, Pichardo T, Mazzilli S, Khan MM, Duggineni VK, Monti S, Sherr DH |
bioRxiv | 2024 |
In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer immunotherapy
Pezzana S, Blaess S, Kortendieck J, Hemmer N, Tako B, Pietura C, Ruoff L, Riel S, Schaller M, Gonzalez-Menendez I, Quintanilla-Martinez L, Mascioni A, Aivazian A, Wilson I, Maurer A, Pichler BJ, Kneilling M, Sonanini D |
Theranostics | 2024 |
CD4(+) T cells in antitumor immunity.
Montauti E, Oh DY, Fong L, Montauti E, Oh DY, Fong L |
Trends in cancer | 2024 |
The role of programmed death receptor (PD-)1/PD-ligand (L)1 in periodontitis and cancer.
Groeger S, Meyle J |
Periodontology 2000 | 2024 |
Telomerase-based vaccines: a promising frontier in cancer immunotherapy
Vahidi S, Zabeti Touchaei A |
Cancer Cell International | 2024 |
Clinical-scale, modular manufacturing of tumor-reactive TILs using a closed and automated culture system
Völzke C, Ehrhardt L, Fischer L, Maul P, Wenzel C, Riabinska A, Criado-Moronati E, Dienstbier M, Hassel J, Zhang D, Haanen JB, Handgretinger R, Hardy IR, Heemskerk B, Dzionek A |
Frontiers in Immunology | 2024 |
CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, Peeters KC, Fariña-Sarasqueta A, Verdegaal EM, van der Burg SH, Duhen T, de Miranda NF |
Journal for ImmunoTherapy of Cancer | 2023 |
PD-1(+)CD8(+) T Cells Proximal to PD-L1(+)CD68(+) Macrophages Are Associated with Poor Prognosis in Pancreatic Ductal Adenocarcinoma Patients.
Yang X, Wang G, Song Y, Zhuang T, Li Y, Xie Y, Fei X, Zhao Y, Xu D, Hu Y |
Cancers | 2023 |
Longitudinal tracking of T cell lymphomas in mice using flow cytometry
Kuczynski EA, Carnevalli L, Sinclair C |
2023 | |
The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR, Chou CH, Liu CJ, Lin YC, Tu HF, Chang KW, Lin SC |
International journal of molecular sciences | 2023 |
Integrated systems immunology approach identifies impaired effector T cell memory responses as a feature of progression to severe dengue fever
Ioannidis LJ, Studniberg SI, Eriksson EM, Suwarto S, Denis D, Liao Y, Shi W, Garnham AL, Sasmono RT, Hansen DS |
Journal of biomedical science | 2023 |
TREM2 mediates MHCII-associated CD4+ T cell response against gliomas
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Dheer A, Gao S, Xu S, Ayasoufi K, Al-kharboosh R, Xie M, Johnson AJ, Dong H, Quiñones-Hinojosa A, Wu LJ |
2023 | |
Spatial distribution of tumor-infiltrating T cells indicated immune response status under chemoradiotherapy plus PD-1 blockade in esophageal cancer
Yan C, Huang H, Zheng Z, Ma X, Zhao G, Zhang T, Chen X, Cao F, Wei H, Dong J, Tang P, Jiang H, Wang M, Wang P, Pang Q, Zhang W |
Frontiers in immunology | 2023 |
Successful ex vivo expansion of tumor infiltrating lymphocytes with systemic chemotherapy prior to surgical resection.
Balzeau J, Ravindran A, Wang X, Maisuria J, Lucchesi A, Yao H, Matsueda S |
Cancer Immunology, Immunotherapy | 2023 |
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C |
BMC Cancer | 2023 |
Activating Inducible T-cell Costimulator Yields Antitumor Activity Alone and in Combination with Anti-PD-1 Checkpoint Blockade
Yadavilli S, Waight JD, Brett S, Bi M, Zhang T, Liu YB, Ellis C, Turner DC, Hahn A, Shi H, Seestaller-Wehr L, Jing J, Xie Q, Shaik JS, Ji X, Gagnon R, Fieles W, Hook L, Grant S, Hopley S, DeYoung MP, Blackwell C, Chisamore M, Biddlecombe R, Figueroa DJ, Hopson CB, Srinivasan R, Smothers J, Maio M, Rischin D, Olive D, Paul E, Mayes PA, Hoos A, Ballas M |
2023 | |
The screening, identification, design and clinical application of tumor-specific neoantigens for TCR-T cells
Li J, Xiao Z, Wang D, Jia L, Nie S, Zeng X, Hu W |
Molecular Cancer | 2023 |
Lineage tracing reveals clonal progenitors and long-term persistence of tumor-specific T cells during immune checkpoint blockade
Pai JA, Hellmann MD, Sauter JL, Mattar M, Rizvi H, Woo HJ, Shah N, Nguyen EM, Uddin FZ, Quintanal-Villalonga A, Chan JM, Manoj P, Allaj V, Baine MK, Bhanot UK, Jain M, Linkov I, Meng F, Brown D, Chaft JE, Plodkowski AJ, Gigoux M, Won HH, Sen T, Wells DK, Donoghue MT, de Stanchina E, Wolchok JD, Loomis B, Merghoub T, Rudin CM, Chow A, Satpathy AT |
Cancer Cell | 2023 |
Identification of aneuploidy-related gene signature to predict survival in head and neck squamous cell carcinomas
Liu Y, Yuan Y, Chen T, Xiao H, Zhang X, Zhang F |
Aging | 2023 |
Unlocking antitumor immunity with adenosine receptor blockers.
Remley VA, Linden J, Bauer TW, Dimastromatteo J |
Cancer drug resistance (Alhambra, Calif.) | 2023 |
TREM2 mediates MHCII-associated CD4+ T-cell response against gliomas
Zheng J, Wang L, Zhao S, Zhang W, Chang Y, Bosco DB, Huang T, Dheer A, Gao S, Xu S, Ayasoufi K, Al-Kharboosh R, Qi F, Xie M, Johnson AJ, Dong H, Quiñones-Hinojosa A, Wu LJ |
Neuro-Oncology | 2023 |
Finding the right help in the tumor microenvironment
Walter Storkus |
Journal of Clinical Investigation | 2022 |
Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer
Jara Palomero, Carla Panisello, Maria Lozano-Rabella, Ricky Tirtakasuma, Judit Díaz-Gómez, Daniela Grases, Helena Pasamar, Laura Arregui, Eduard Dorca Duch, Esther Guerra Fernández, Ana Vivancos, Carlos Andrea, Ignacio Melero, Jordi Ponce, August Vidal, Josep Piulats, Xavier Matias-Guiu, Alena Gros |
Journal for ImmunoTherapy of Cancer | 2022 |
Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer
Bryan Bell |
Journal of Clinical Investigation | 2022 |
Development and therapeutic manipulation of the head and neck cancer tumor environment to improve clinical outcomes.
Duhen T, Gough MJ, Leidner RS, Stanton SE |
2022 | |
ICOS is upregulated on T cells following radiation and agonism combined with radiation results in enhanced tumor control
Blair T, Baird J, Bambina S, Kramer G, Gostissa M, Harvey CJ, Gough MJ, Crittenden MR |
Scientific Reports | 2022 |
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, Wu W, Han L, Wang S |
Frontiers in immunology | 2022 |
Potential biomarkers: Identifying powerful tumor specific T cells in adoptive cellular therapy
Ge W, Dong Y, Deng Y, Chen L, Chen J, Liu M, Wu J, Wang W, Ma X |
Frontiers in immunology | 2022 |